keyword
MENU ▼
Read by QxMD icon Read
search

Anidulafungin

keyword
https://www.readbyqxmd.com/read/28419092/a-multi-centric-study-of-candida-bloodstream-infection-in-lima-callao-peru-species-distribution-antifungal-resistance-and-clinical-outcomes
#1
Lourdes Rodriguez, Beatriz Bustamante, Luz Huaroto, Cecilia Agurto, Ricardo Illescas, Rafael Ramirez, Alberto Diaz, Jose Hidalgo
BACKGROUND: The incidence of candidemia is increasing in developing countries. Very little is known about the epidemiology of candidemia in Peru. The aim of this study is to describe the incidence, microbiology, clinical presentation and outcomes of Candida bloodstream infections in three Lima-Callao hospitals. METHODS: Candida spp. isolates were identified prospectively at participant hospitals between November 2013 and January 2015. Susceptibility testing for amphotericin B, fluconazole, posaconazole, voriconazole and anidulafungin was performed using broth microdilution method...
2017: PloS One
https://www.readbyqxmd.com/read/28416539/candida-auris-comparison-of-the-eucast-and-clsi-reference-microdilution-mics-for-eight-antifungal-compounds-and-associated-tentative-ecoffs
#2
M C Arendrup, Anupam Prakash, Joseph Meletiadis, Cheshta Sharma, Anuradha Chowdhary
C. auris is an emerging multidrug-resistant yeast. So far, all but two susceptibility testing studies have examined ≤50 isolates and mostly with the CLSI method. We investigated CLSI and EUCAST MICs for 123 C. auris isolates and eight antifungals and evaluated various methods for ECOFF determination.MICs (mg/L) were determined using CLSI M27-A3 and EUCAST E.Def 7.3. ANOVA analysis with Bonferroni's multiple comparison test and Pearson analysis were used on log2MICs (significant, p<0.05). The percent agreement (±0->2 two-fold dilutions) between the methods was calculated...
April 17, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28365835/paecilomyces-variotii-fungemia-in-a-patient-with-lymphoma-needing-liver-transplant
#3
A P Bellanger, J P Cervoni, J F Faucher, D Weil-Verhoeven, M Ginet, E Deconinck, F Grenouillet
Paecilomyces sp. are emerging pathogens in immunocompromised patients. We report here a case of Paecilomyces variotii fungemia, cured with amphotericin and anidulafungin, illustrating difficulties of early diagnosis and therapeutic choice in such rare fungal infection.
April 1, 2017: Mycopathologia
https://www.readbyqxmd.com/read/28364558/changing-epidemiology-of-candidaemia-in-australia
#4
Belinda Chapman, Monica Slavin, Debbie Marriott, Catriona Halliday, Sarah Kidd, Ian Arthur, Narin Bak, Christopher H Heath, Karina Kennedy, C Orla Morrissey, Tania C Sorrell, Sebastian van Hal, Caitlin Keighley, Emma Goeman, Neil Underwood, Krispin Hajkowicz, Ann Hofmeyr, Michael Leung, Nenad Macesic, Jeannie Botes, Christopher Blyth, Louise Cooley, C Robert George, Pankaja Kalukottege, Alison Kesson, Brendan McMullan, Robert Baird, Jennifer Robson, Tony M Korman, Stella Pendle, Kerry Weeks, Eunice Liu, Elaine Cheong, Sharon Chen
Objectives: Knowledge of contemporary epidemiology of candidaemia is essential. We aimed to identify changes since 2004 in incidence, species epidemiology and antifungal susceptibilities of Candida spp. causing candidaemia in Australia. Methods: These data were collected from nationwide active laboratory-based surveillance for candidaemia over 1 year (within 2014-2015). Isolate identification was by MALDI-TOF MS supplemented by DNA sequencing. Antifungal susceptibility testing was performed using Sensititre YeastOne™...
April 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28356416/in-vitro-antifungal-susceptibility-of-the-yeast-and-mould-phases-of-the-dimorphic-fungal-pathogen-emergomyces-africanus-formerly-emmonsia-species-from-hiv-infected-south-african-patients
#5
Tsidiso G Maphanga, Erika Britz, Thokozile G Zulu, Ruth S Mpembe, Serisha D Naicker, Ilan S Schwartz, Nelesh P Govender
Introduction: Disseminated emmonsiosis is an important AIDS-related mycosis in South Africa caused by Emergomyces africanus, a newly-described and -renamed dimorphic fungal pathogen. In vitro antifungal susceptibility data can guide management.Materials and Methods: Identification of invasive clinical isolates was confirmed phenotypically and by sequencing the internal transcribed spacer region. Yeast and mould-phase MICs for fluconazole, voriconazole, itraconazole, posaconazole, caspofungin, anidulafungin, micafungin and flucytosine were determined using custom-made frozen broth microdilution (BMD) panels, as per Clinical and Laboratory Standards Institute recommendations...
March 29, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/28355467/new-pharmacological-opportunities-for-the-treatment-of-invasive-mould-diseases
#6
Marie-Pierre Ledoux, Elise Toussaint, Julie Denis, Raoul Herbrecht
Recently, several randomized studies have been published that will shape treatment decisions in the prevention and management of invasive mould infections. Liposomal amphotericin B is an option for empirical or targeted treatment of invasive aspergillosis or mucormycosis, but for prophylaxis therapy, the triazole class now predominates. The triazole voriconazole is currently regarded as a drug of choice for the treatment of proven or probable invasive aspergillosis, and has shown significantly higher response rates than amphotericin B deoxycholate in this setting, with fewer severe drug-related adverse events...
March 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28330883/comparative-evaluation-of-sensititre-yeastone%C3%A2-and-clsi-m38-a2-reference-method-for-antifungal-susceptibility-testing-of-aspergillus-spp-against-echinocandins
#7
Maria Siopi, Spyros Pournaras, Joseph Meletiadis
Sensititre YeastOne® (YO) panels were assessed for in vitro susceptibility testing of echinocandins against 39 isolates of A. fumigatus, A. flavus and A. terreus, including two echinocandin-resistant A. fumigatus, using different inocula (10(3), 10(4) and 10(5) cfu/mL), incubation times (16-48h) and endpoints (first blue or purple) and compared with CLSI M38-A2. The best agreement was found with inoculum of 10(4) cfu/mL, incubation time of 20h for A. flavus and 30h for A. fumigatus and A. terreus and reading the first purple well...
March 22, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/28264849/genetic-diversity-and-in-vitro-antifungal-susceptibility-of-200-clinical-and-environmental-aspergillus-flavus-isolates
#8
Mojtaba Taghizadeh-Armaki, Mohammad Taghi Hedayati, Saham Ansari, Saeed Mahdavi Omran, Sasan Saber, Haleh Rafati, Jan Zoll, Henrich A van der Lee, Willem J G Melchers, Paul E Verweij, Seyedmojtaba Seyedmousavi
Aspergillus flavus has been frequently reported as the leading cause of invasive aspergillosis in certain tropical and sub-tropical countries.Two hundred A. flavus strains originating from clinical and environmental sources and collected between 2008 and 2015 were phylogenetically identified at the species level by analyzing partial β-tubulin and calmodulin genes. In vitro antifungal susceptibility testing was performed against antifungals using the EUCAST (European Committee on Antimicrobial Susceptibility Testing) broth microdilution method...
March 6, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28257903/does-a-triple-combination-have-better-activity-than-double-combinations-against-multiresistant-fungi-experimental-in-vitro-evaluation
#9
Adela Martin-Vicente, Josep Guarro, Javier Capilla
In this study, the in vitro interactions of amphotericin B (AmB), voriconazole (VRC) and anidulafungin (AFG) in double and triple combinations against four species of multiresistant fungi (Fusarium solani, Lomentospora prolificans, Scopulariopsis brevicaulis and Scopulariopsis brumptii) were evaluated. In general, AmB combined with AFG was the most synergistic, especially against F. solani (7/8; 87.5%) when low concentrations of AmB were used, i.e. 0.125-0.5 µg/mL. The least active combination was AmB + VRC, with the lowest percentage of synergy against S...
April 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28180946/new-developments-and-directions-in-the-clinical-application-of-the-echinocandins
#10
REVIEW
C C Chang, M A Slavin, S C-A Chen
The echinocandins-caspofungin, anidulafungin and micafungin-are semi-synthetic cyclic hexapeptide antimicrobial agents with modified N-linked acyl lipid side chains which anchor the compounds to the phospholipid bilayer of the fungal cell membrane, thereby inhibiting synthesis of fungal cell wall glucan. Over the last 10 years, echinocandins have become the first-line antifungal treatment of candidaemia and other forms of invasive candidiasis (IC). Echinocandins are generally well tolerated, but their use is limited by their requirement for daily intravenous dosing, lack of oral formulation and limited spectrum...
February 8, 2017: Archives of Toxicology
https://www.readbyqxmd.com/read/28150341/invasive-infections-due-to-saprochaete-and-geotrichum-species-report-of-23-cases-from-the-fungiscope-registry
#11
Luisa Durán Graeff, Danila Seidel, Maria J G T Vehreschild, Axel Hamprecht, Anupma Kindo, Zdenek Racil, Judit Demeter, Sybren De Hoog, Ute Aurbach, Maren Ziegler, Hilmar Wisplinghoff, Oliver A Cornely
Saprochaete and Geotrichum spp. are rare emerging fungi causing invasive fungal diseases in immunosuppressed patients and scarce evidence is available for treatment decisions. Among 505 cases of rare IFD from the FungiScope(™) registry, we identified 23 cases of invasive infections caused by these fungi reported from 10 countries over a 12-year period. All cases were adults and previous chemotherapy with associated neutropenia was the most common co-morbidity. Fungaemia was confirmed in 14 (61%) cases and deep organ involvement included lungs, liver, spleen, central nervous system and kidneys...
April 2017: Mycoses
https://www.readbyqxmd.com/read/28137817/pharmacokinetics-of-the-novel-echinocandin-cd101-in-multiple-animal-species
#12
Voon Ong, Kenneth D James, Steven Smith, B Radha Krishnan
CD101 is a novel semisynthetic echinocandin with antifungal activity against Candida and Aspergillus spp. The pharmacokinetics (PK) of CD101 administered intravenously to mice, rats, dogs, cynomolgus monkeys, and chimpanzees are presented. CD101 consistently exhibited very low clearance, a modest volume of distribution at steady state (Vss), and a long half-life (t1/2) across all species tested. In mouse, rat, dog, cynomolgus monkey, and chimpanzee, CD101 clearance was 0.10, 0.47, 0.30, 0.41, and 0.06 ml/min/kg, respectively; Vss was 206, 1,390, not determined, 597, and 400 ml/kg, respectively; and t1/2 was 25, 39, 53, 40, and 81 h, respectively...
April 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28115858/cost-effectiveness-analysis-of-combination-antifungal-therapy-with-voriconazole-and-anidulafungin-versus-voriconazole-monotherapy-for-primary-treatment-of-invasive-aspergillosis-in-spain
#13
Santiago Grau, Jose Ramon Azanza, Isabel Ruiz, Carlos Vallejo, Josep Mensa, Johan Maertens, Werner J Heinz, Jon Andoni Barrueta, Carmen Peral, Francisco Jesús Mesa, Miguel Barrado, Claudie Charbonneau, Darío Rubio-Rodríguez, Carlos Rubio-Terrés
OBJECTIVE: According to a recent randomized, double-blind clinical trial comparing the combination of voriconazole and anidulafungin (VOR+ANI) with VOR monotherapy for invasive aspergillosis (IA) in patients with hematologic disease or with hematopoietic stem cell transplant, mortality was lower after 6 weeks with VOR+ANI than with VOR monotherapy in a post hoc analysis of patients with galactomannan-based IA. The objective of this study was to compare the cost-effectiveness of VOR+ANI with VOR, from the perspective of hospitals in the Spanish National Health System...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28088767/pharmacokinetic-study-of-anidulafungin-in-icu-patients-with-intra-abdominal-candidiasis
#14
H Dupont, L Massias, B Jung, N Ammenouche, P Montravers
BACKGROUND: Only limited pharmacokinetic data are available for anidulafungin in ICU patients, especially in patients treated for severe intra-abdominal infection (IAI). METHODS: This was a prospective multicentre observational study in ICU patients with suspected yeast IAI. All patients received an intravenous loading dose of 200 mg of anidulafungin, followed by 100 mg/day. Thirteen blood samples were drawn between day 1 and day 5 for pharmacokinetic analysis...
January 14, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28053212/multilocus-phylogeny-and-antifungal-susceptibility-of-aspergillus-section-circumdati-from-clinical-samples-and-description-of-a-pseudosclerotiorum-sp-nov
#15
J P Z Siqueira, D A Sutton, J Gené, D García, N Wiederhold, S W Peterson, J Guarro
A multilocus phylogenetic study was carried out to assess species identity of a set of 34 clinical isolates from Aspergillus section Circumdati from the United States and to determine their in vitro antifungal susceptibility against eight antifungal drugs. The genetic markers used were the internal transcribed spacer (ITS) region, and fragments of the beta-tubulin (BenA), calmodulin (CaM), and RNA polymerase II second largest subunit (RPB2) genes. The drugs tested were amphotericin B, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, micafungin, and terbinafine...
March 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/28052853/activity-of-a-long-acting-echinocandin-cd101-and-seven-comparator-antifungal-agents-tested-against-a-global-collection-of-contemporary-invasive-fungal-isolates-in-the-sentry-2014-antifungal-surveillance-program
#16
Michael A Pfaller, Shawn A Messer, Paul R Rhomberg, Mariana Castanheira
The activity of CD101 and comparator antifungal agents against 606 invasive fungal isolates collected worldwide during 2014 was evaluated using the Clinical and Laboratory Standards Institute (CLSI) method. All Candida albicans (n = 251), Candida tropicalis (n = 51), Candida krusei (n = 16), and Candida dubliniensis (n = 11) isolates were inhibited by ≤0.12 μg/ml of CD101 and were susceptible or showed wild-type susceptibility to the other echinocandins tested. Five C. glabrata isolates (n = 100) displayed CD101 MIC values of 1 to 4 μg/ml, had elevated MICs of caspofungin (2 to >8 μg/ml), anidulafungin (2 to 4 μg/ml), and micafungin (2 to 4 μg/ml), and carried mutations on fks1 and fks2Candida parapsilosis (n = 92) and Candida orthopsilosis (n = 10) displayed higher CD101 MIC values (ranges, 0...
March 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28031205/in-vitro-activity-of-posaconazole-against-talaromyces-marneffei-by-broth-microdilution-and-etest-methods-and-comparison-to-itraconazole-voriconazole-and-anidulafungin
#17
Susanna K P Lau, George C S Lo, Clare S K Lam, Wang-Ngai Chow, Antonio H Y Ngan, Alan K L Wu, Dominic N C Tsang, Cindy W S Tse, Tak-Lun Que, Bone S F Tang, Patrick C Y Woo
We determined the susceptibilities of 57 Talaromyces marneffei strains to anidulafungin, itraconazole, voriconazole, and posaconazole with MICs of 2 to 8, 0.002 to 0.004, 0.016 to 0.063, and 0.001 to 0.002 μg/ml by broth microdilution and >32, ≤0.002 to 0.008, ≤0.002 to 0.008, and ≤0.002 μg/ml by Etest, respectively, at yeast phase; MICs at mycelial phase for anidulafungin and posaconazole were 1 to 2 and 0.004 to 0.063 μg/ml, respectively. The results suggest promising activities of posaconazole...
March 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28011902/ecil-6-guidelines-for-the-treatment-of-invasive-candidiasis-aspergillosis-and-mucormycosis-in-leukemia-and-hematopoietic-stem-cell-transplant-patients
#18
Frederic Tissot, Samir Agrawal, Livio Pagano, Georgios Petrikkos, Andreas H Groll, Anna Skiada, Cornelia Lass-Flörl, Thierry Calandra, Claudio Viscoli, Raoul Herbrecht
The European Conference on Infections in Leukemia (ECIL) provides recommendations for diagnostic strategies and prophylactic, pre-emptive or targeted therapy strategies for various types of infection in patients with hematologic malignancies or hematopoietic stem cell transplantation recipients. Meetings are held every two years since 2005 and evidence-based recommendations are elaborated after evaluation of the literature and discussion among specialists of nearly all European countries. In this manuscript, the ECIL group presents the 2015-update of the recommendations for the targeted treatment of invasive candidiasis, aspergillosis and mucormycosis...
March 2017: Haematologica
https://www.readbyqxmd.com/read/27919891/structure-activity-relationships-of-a-series-of-echinocandins-and-the-discovery-of-cd101-a-highly-stable-and-soluble-echinocandin-with-distinctive-pharmacokinetic-properties
#19
Kenneth D James, Christopher P Laudeman, Navdeep B Malkar, Radha Krishnan, Karen Polowy
Echinocandins are a first-line therapy for candidemia and invasive candidiasis. They are generally safe with few drug interactions, but the stability and pharmacokinetic properties of currently approved echinocandins are such that each was developed for daily intravenous infusion. We sought to discover a novel echinocandin with properties that would enable more flexible dosing regimens, alternate routes of delivery, and expanded utility. Derivatives of known echinocandin scaffolds were generated, and an iterative process of design and screening led to the discovery of CD101, a novel echinocandin that has since demonstrated improved chemical stability and pharmacokinetics...
February 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27904738/recent-developments-in-the-management-of-invasive-fungal-infections-in-patients-with-oncohematological-diseases
#20
REVIEW
Markus Ruhnke, Stefan Schwartz
Patients with hematological cancer have a high risk of invasive fungal diseases (IFDs). These infections are mostly life threatening and an early diagnosis and initiation of appropriate antifungal therapy are essential for the clinical outcome. Most commonly, Aspergillus and Candida species are involved. However, other non-Aspergillus molds are increasingly be identified in cases of documented IFDs. Important risk factors are long lasting granulocytopenia with neutrophil counts below 500/μl for more than 10 days or graft-versus-host disease resulting from allogeneic stem-cell transplantation...
December 2016: Therapeutic Advances in Hematology
keyword
keyword
54240
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"